{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:00:11Z","timestamp":1792616411117,"version":"4.5.0"},"reference-count":40,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,1,29]],"date-time":"2018-01-29T00:00:00Z","timestamp":1517184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30DK42086"],"award-info":[{"award-number":["P30DK42086"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08DK090152"],"award-info":[{"award-number":["K08DK090152"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Blocking of lymphocyte trafficking to bile ducts is a potential mechanism to alter the disease course of patients with primary sclerosing cholangitis (<jats:styled-content style=\"fixed-case\">PSC<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To describe the effect of the \u03b1<jats:sub>4<\/jats:sub>\u03b2<jats:sub>7<\/jats:sub> integrin antibody, vedolizumab, on liver biochemistry and disease activity in patients with <jats:styled-content style=\"fixed-case\">PSC<\/jats:styled-content> and inflammatory bowel disease (<jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a retrospective multi\u2010centre study of adult patients with a diagnosis of both <jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">PSC<\/jats:styled-content>. The primary outcome was change in serum alkaline phosphatase level at weeks 14 and 30. Secondary outcomes included changes in other liver biochemistries and in clinical outcomes for the bowel disease. A safety analysis for adverse events was performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty\u2010four patients (16 Crohn's disease, 18 ulcerative colitis) were included. Nine (26%) had a history of liver transplant. Median follow\u2010up on vedolizumab was 9 months (<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content>: 7\u201016). There was no overall change in serum alkaline phosphatase level with vedolizumab therapy (median 268 [<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content>: 105\u2010551] <jats:styled-content style=\"fixed-case\">IU<\/jats:styled-content>\/L at baseline versus 249 [<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content>: 183\u2010634] <jats:styled-content style=\"fixed-case\">IU<\/jats:styled-content>\/L, <jats:italic>P<\/jats:italic> = 0.99 at week 30). No significant changes in other liver biochemistries or the Mayo <jats:styled-content style=\"fixed-case\">PSC<\/jats:styled-content> Risk Score were demonstrated at week 30. Clinical remission was achieved at week 30 in 55% of Crohn's disease and 29% of ulcerative colitis patients. Seven (21%) patients ceased vedolizumab; six patients stopped therapy due to persistent <jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content> activity and one for worsening of liver biochemistries.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Vedolizumab treatment in patients with <jats:styled-content style=\"fixed-case\">PSC<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content> did not improve liver biochemistry but was associated with improvement in bowel disease and a favourable safety profile.<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.14525","type":"journal-article","created":{"date-parts":[[2018,1,29]],"date-time":"2018-01-29T21:34:55Z","timestamp":1517261695000},"page":"753-762","source":"Crossref","is-referenced-by-count":82,"title":["Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease"],"prefix":"10.1111","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8746-4275","authenticated-orcid":false,"given":"B.","family":"Christensen","sequence":"first","affiliation":[{"name":"Alfred Hospital and Monash University Melbourne Australia"},{"name":"Royal Melbourne Hospital Melbourne Australia"},{"name":"University of Chicago Medicine Inflammatory Bowel Disease Center Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Micic","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. R.","family":"Gibson","sequence":"additional","affiliation":[{"name":"Alfred Hospital and Monash University Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Yarur","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Medical College of Wisconsin Milwaukee WI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bellaguarda","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Corsello","sequence":"additional","affiliation":[{"name":"University of Michigan Health System Ann Arbor MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. N.","family":"Gaetano","sequence":"additional","affiliation":[{"name":"University of Chicago Medicine Inflammatory Bowel Disease Center Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kinnucan","sequence":"additional","affiliation":[{"name":"University of Michigan Health System Ann Arbor MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. L.","family":"Rao","sequence":"additional","affiliation":[{"name":"University of Chicago Medicine Inflammatory Bowel Disease Center Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Reddy","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Singh","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Medical College of Wisconsin Milwaukee WI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Pekow","sequence":"additional","affiliation":[{"name":"University of Chicago Medicine Inflammatory Bowel Disease Center Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. T.","family":"Rubin","sequence":"additional","affiliation":[{"name":"University of Chicago Medicine Inflammatory Bowel Disease Center Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,1,29]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60096-3"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.22938"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.06.052"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(90)91096-O"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.36088"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199703063361003"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23082"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12639"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215734"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215739"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.236"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20041035"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.1999.tb00084.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000906"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(16)33623-X"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.082909"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840100102"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)92767-1"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.43.1.29"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5107(04)01878-4"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198712243172603"},{"key":"e_1_2_7_23_1","first-page":"287","volume-title":"Crohn's Disease & Ulcerative Colitis","author":"Joseph N","year":"2011"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12979"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840160315"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.27965"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.08.017"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.156"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04863.x"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040622315605821"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.02.016"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv226"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13594"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13813"},{"key":"e_1_2_7_35_1","article-title":"\u2018Patients with ulcerative colitis and primary sclerosing cholangitis frequently have subclinical inflammation in the proximal colon\u2019","author":"Cleveland NK","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.11.010"},{"key":"e_1_2_7_37_1","first-page":"522","article-title":"Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis?","volume":"41","author":"Kornfeld D","year":"1997","journal-title":"A population based study. Gut"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-311079"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000001039"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000561"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(15)32937-1"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.14525","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.14525","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T07:11:23Z","timestamp":1694329883000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.14525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,29]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1111\/apt.14525"],"URL":"https:\/\/doi.org\/10.1111\/apt.14525","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,29]]}}}